Background: Catestatin has been reported as a pleiotropic cardioprotective peptide. Heart failure with preserved ejection fraction (HFpEF) was considered a heterogeneous syndrome with a complex cause. We sought to investigate the role of catestatin in HFpEF and diastolic dysfunction. METHODS AND RESULTS: Administration of recombinant catestatin (1.5 mg/kg/d) improved diastolic dysfunction and left ventricular chamber stiffness in transverse aortic constriction mice with deoxycorticosterone acetate pellet implantation, as reflected by Doppler tissue imaging and pressure‐volume loop catheter. Less cardiac hypertrophy and myocardial fibrosis was observed, and transcriptomic analysis revealed downregulation of mitochondrial electron transport chain components after catestatin treatment. Catestatin reversed mitochondrial structural and respiratory chain component abnormality, decreased mitochondrial proton leak, and reactive oxygen species generation in myocardium. Excessive oxidative stress induced by Ru360 abolished catestatin treatment effects on HFpEF‐like cardiomyocytes in vitro, indicating the beneficial role of catestatin in HFpEF as a mitochondrial ETC modulator. The serum concentration of catestatin was tested among 81 patients with HFpEF and 76 non–heart failure controls. Compared with control subjects, serum catestatin concentration was higher in patients with HFpEF and positively correlated with E velocity to mitral annular e′ velocity ratio, indicating a feedback compensation role of catestatin in HFpEF. Conclusions: Catestatin protects against diastolic dysfunction in HFpEF through attenuating mitochondrial electron transport chain–derived reactive oxygen species generation. Serum catestatin concentration is elevated in patients with HFpEF, probably as a relatively insufficient but self‐compensatory mechanism.
8 October 2025 in Frontiers in Cardiovascular Medicine
Danon Disease (DD) is a rare X-linked inherited disorder caused by severe deficiency of lysosome-associated membrane protein-2 (LAMP-2), encoded by the LAMP2 gene. Characteristic clinical features include a triad of cardiomyopathy, skeletal myopathy and cognitive impairment in males. Females usually exhibit milder, cardiac-predominant manifestations later in life. In this case, we report a 30-year-old woman with a novel suspected pathogenic LAMP2 mutation (c.1A > T, initiation codon mutation). She developed Wolff-Parkinson-White (WPW) syndrome in her twenties, acute heart failure post cesarean section at age 29, and persistent left ventricular hypertrophy. Positive result of Technetium-99 m pyrophosphate (99mTc-PYP) scintigraphy strongly indicated transthyretin amyloid cardiomyopathy (ATTR-CM). However, whole-exome sequencing (WES) identified the novel A to T transition in initiation codon (c.1A > T) of LAMP2 gene, establishing the diagnosis of DD and revealing the false-positive result of PYP scintigraphy in DD.
10 June 2026 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
To show that heart failure with supranormal ejection fraction (HFsnEF, left ventricular ejection fraction [LVEF] ≥ 65%) is not a marker of cardiac health but a specific enrichment zone for malignant cardiomyopathies and to provide a phenotypic framework for differential diagnosis. We retrospectively analyzed 200 consecutive patients with HFsnEF admitted between December 1, 2017 and December 1, 2024. Patients were stratified into 2 phenotypes based on etiology: group A (hemodynamic loading, n=88), comprising valvular or hypertensive heart disease; and group B (intrinsic cardiomyopathy, n=112), comprising hypertrophic cardiomyopathy, cardiac amyloidosis, or Fabry disease. We compared their electromechanical profiles and event-free survival. Despite identical LVEF (median, 69%), the 2 groups exhibited distinct clinical signatures. Group A represented a classic secondary remodeling profile (older age and atrial fibrillation). In contrast, group B patients were younger (56.0 vs 68.8 years; P<.001) yet displayed severe diastolic stiffness (septal E/e' > 13) and a distinct electromechanical fingerprint (wide QRS or PR deviations). In a fully adjusted multivariable Cox model, the intrinsic cardiomyopathy phenotype was the dominant driver of the composite end point (adjusted hazards ratio, 3.91; 95% CI, 1.71-8.93; P = .001). Notably, N-terminal pro–B-type natriuretic peptide was not an independent predictor (P = .20) in this population, indicating that structural etiology overrides hemodynamic biomarkers in determining prognosis. An LVEF of 65% or more is not reassuring but signals underlying heterogeneity, often masking malignant intrinsic cardiomyopathies that masquerade as benign heart failure with preserved ejection fraction. A multimodal red flag approach—integrating clinical, imaging, and electrocardiographic data—is essential to trigger targeted evaluation, as standard heart failure with preserved ejection fraction management is insufficient for these high-risk phenotypes.